Recursion Pharmaceuticals
Recursion Pharmaceuticals raises $239M Series F at $4B valuation
Recursion Pharmaceuticals: Series F Funding Round
Recursion Pharmaceuticals has successfully raised $239M in Series F funding, reaching a valuation of $4B.
Company Overview
AI-powered drug discovery
Funding Details
The Series F round was led by Baillie Gifford, with participation from ARK Investment Management, Mubadala Capital, Kinnevik, Catalio Capital Management.
Company Information
- Headquarters: 41 South Rio Grande Street, Salt Lake City, UT 84101
- Founded: 2013
- Employees: 500+
- Category: Biotech
Investment
Recursion Pharmaceuticals plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Baillie Gifford: Verified investor in Series F
- ARK Investment Management: Verified investor in Series F
- Mubadala Capital: Verified investor in Series F
- Kinnevik: Verified investor in Series F
- Catalio Capital Management: Verified investor in Series F
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started